If you have been reading about hexenoyl group and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-15. Numbers and descriptions here follow the published literature rather than marketing material.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | 2 to 8 °C | Refrigerated, protected from light |
| Appearance | White to off-white powder | Lyophilized cake in a single-use vial |
| Solubility | Soluble in water | Yields a clear solution after reconstitution |
| Identity method | Electrospray mass spectrometry | Confirms the expected molecular mass |
| Purity method | Reversed-phase HPLC | Reports main peak against related substances |
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Fast CFDs of advanced designs have the dead times equal to or less than two single-hit response times of the ion detector (single-hit response time for MCP with 2-5 micron wide channels can be somewhere between 0.2 ns and 0.8 ns, depending on the channel angle) thus preventing repetitive triggering from the same pulse. Double-hit resolution (dead time) of modern multi-hit TDC can be as low as 3-5 nanosecond. The TDC is a counting detector – it can be extremely fast (down to a few picosecond resolution), but its dynamic range is limited due to its inability to properly count the events when more than one ion simultaneously (i.e., within the TDC dead time) hit the detector. The outcome of limited dynamic range is that the number of ions (events) recorded in one mass spectrum is smaller compared to real number. The problem of limited dynamic range can be alleviated using multichannel detector design: an array of mini-anodes attached to a common MCP stack and multiple CFD/TDC, where each CFD/TDC records signals from individual mini-anode. To obtain peaks with statistically acceptable intensities, ion counting is accompanied by summing of hundreds of individual mass spectra (so-called hystograming). To reach a very high counting rate (limited only by duration of individual TOF spectrum which can be as high as few milliseconds in multipath TOF setups), a very high repetition rate of ion extractions to the TOF tube is used. Commercial orthogonal acceleration TOF mass analyzers typically operate at 5–20 kHz repetition rates.
==== Elimination ==== The drug exhibits non-linear pharmacokinetics. Upon multiple dosing, the accumulation of ritonavir is lower than predicted from a single dose, which is possibly due to a time- and dose-related increase in drug clearance. The circulating half-life of ritonavir is typically 3 to 5 hours. Elimination occurs primarily via the feces (86.4 ± 2.9%, with 33.8 ± 10.8% excreted as unchanged parent drug), while a smaller fraction is excreted in the urine (11.3 ± 2.8%, with 3.5 ± 1.8% as unchanged parent drug).
== Early life and education == James Orsen Bakker was born in Muskegon, Michigan, the son of Raleigh Bakker and Furnia Lynette "Furn" Irwin. Bakker attended North Central University, a Minneapolis Bible college affiliated with the Assemblies of God, where he met fellow student Tammy Faye LaValley in 1960. Bakker worked at a restaurant in the Young-Quinlan department store in Minneapolis; Tammy Faye worked at the Three Sisters, a nearby boutique. Despite already having a fiancée in Muskegon, Jim began courting Tammy Faye. The Bakkers married on April 1, 1961, and left college to become itinerant evangelists. They had two children, Tammy Sue "Sissy" Bakker Chapman (born March 2, 1970) and Jamie Charles "Jay" Bakker (born December 18, 1975). The couple divorced on March 13, 1992. On September 4, 1998, Bakker married Lori Beth Graham, a former televangelist, fifty days after they met. In 2002, they adopted five children, siblings whom Lori had befriended in Phoenix.
== Droplet manipulation == The benefits of microfluidics can be scaled up to higher throughput using larger channels to allow more droplets to pass or by increasing droplet size. Droplet size can be tuned by adjusting the rate of flow of the continuous and disperse phases, but droplet size is limited by the need to maintain the concentration, inter-analyte distances, and stability of microdroplets. Thus, increased channel size becomes attractive due to the ability to create and transport a large number of droplets, though dispersion and stability of droplets become a concern. Finally, thorough mixing of droplets to expose the greatest possible number of reagents is necessary to ensure the maximum amount of starting materials react. This can be accomplished by using a windy channel to facilitate unsteady laminar flow within the droplets.
== History == Pantoprazole was discovered by scientists at Byk Gulden, a subsidiary of Altana; the drug discovery program started in 1980, producing pantoprazole in 1985. The compound was actually created by chemists working to scale up a different chemical that had been chosen as a development candidate. Byk Gulden partnered with Smith Kline & French in 1984. The compound's development names were BY1029 and SK&F96022. By 1986 the companies had created the sodium salt, pantoprazole sodium sesquihydrate, and decided to develop it as it was more soluble and stable, and was more compatible with other ingredients used in the formulation. It was first marketed in Germany in 1994. Wyeth licensed the US patent from Altana, and obtained marketing approval from the US FDA in 2000 under the trade name Protonix. In 2004, worldwide sales of the drug were $3.65 billion, about half of which were in the US. In 2007, Altana's drug business was acquired by Nycomed. Nycomed was in turn acquired by Takeda in 2011 and Wyeth was acquired by Pfizer in 2009. The patent protecting the drug was set to expire in 2010, but Teva Pharmaceuticals filed an Abbreviated New Drug Application (ANDA) in 2007, and Wyeth and Nycomed sued Teva for patent infringement, but Teva decided to launch its generic drug "at risk" that year, before the patent had been invalidated. Wyeth launched an authorized generic in 2008. Pfizer and Takeda's patent exclusivity expired in 2010, and an administrative exclusivity they had for pediatric use expired in January 2011, and full generic competition began.
Sources: en.wikipedia.org
In contrast to product requirements or other laws that hinder market access, the Court of Justice developed a presumption that "selling arrangements" would be presumed to not fall into TFEU article 34, if they applied equally to all sellers, and affected them in the same manner in fact. In Keck and Mithouard two importers claimed that their prosecution under a French competition law, which prevented them selling Picon beer under wholesale price, was unlawful. The aim of the law was to prevent cut throat competition, not to hinder trade. The Court of Justice held, as "in law and in fact" it was an equally applicable "selling arrangement" (not something that alters a product's content) it was outside the scope of article 34, and so did not need to be justified. Selling arrangements can be held to have an unequal effect "in fact" particularly where traders from another member state are seeking to break into the market, but there are restrictions on advertising and marketing. In Konsumentombudsmannen v De Agostini the Court of Justice reviewed Swedish bans on advertising to children under age 12, and misleading commercials for skin care products. While the bans have remained (justifiable under article 36 or as a mandatory requirement) the Court emphasised that complete marketing bans could be disproportionate if advertising were "the only effective form of promotion enabling [a trader] to penetrate" the market.
=== Youth councils === Under the terms of the Local Government Act 2002, district councils have to represent the interests of their future communities and consider the views of people affected by their decisions. To fulfill that requirement and give young people a say in the decision-making process, many councils have a youth council. In late December 2023, the Ashburton District Council scrapped their youth council, stating they could engage better with younger people online and describing the current youth council as "a youth club where they ate pizza." In early January 2024, the Gore District Council opted to restructure its youth council and ruled out dismantling it. In April 2024, the Whanganui District Council proposed scrapping its youth council by June 2024 as part of budget saving measures.
The renin–angiotensin–aldosterone system is a major blood pressure regulating mechanism. Markers of electrolyte and water imbalance in the body such as hypotension, low distal tubule sodium concentration, decreased blood volume and high sympathetic tone trigger the release of the enzyme renin from the cells of juxtaglomerular apparatus in the kidney. Renin activates a circulating liver derived prohormone angiotensinogen by proteolytic cleavage of all but its first ten amino acid residues known as angiotensin I. ACE (angiotensin converting enzyme) then removes a further two residues, converting angiotensin I into angiotensin II. ACE is found in the pulmonary circulation and in the endothelium of many blood vessels. The system increases blood pressure by increasing the amount of salt and water the body retains. Angiotensin II is also a potent vasoconstrictor.
Nicotine, which is contained in cigarettes and other smoked tobacco products, is a stimulant and is one of the main factors leading to continued tobacco smoking. Nicotine is a highly addictive psychoactive chemical. When tobacco is smoked, most of the nicotine is pyrolyzed; a dose sufficient to cause mild somatic dependency and mild to strong psychological dependency remains. The amount of nicotine absorbed by the body from smoking depends on many factors, including the type of tobacco, whether the smoke is inhaled, and whether a filter is used. There is also a formation of harmane (a MAO inhibitor) from the acetaldehyde in cigarette smoke, which seems to play an important role in nicotine addiction probably by facilitating dopamine release in the nucleus accumbens in response to nicotine stimuli. According to studies by Henningfield and Benowitz, nicotine is more addictive than cannabis, caffeine, alcohol, cocaine, and heroin when considering both somatic and psychological dependence. However, due to the stronger withdrawal effects of alcohol, cocaine and heroin, nicotine may have a lower potential for somatic dependence than these substances. About half of Canadians who currently smoke have tried to quit. McGill University health professor Jennifer O'Loughlin stated that nicotine addiction can occur as soon as five months after the start of smoking.
The FDA responded to the report by stating: Aspartame being labeled by IARC as "possibly carcinogenic to humans" does not mean that aspartame is actually linked to cancer. The FDA disagrees with IARC's conclusion that these studies support classifying aspartame as a possible carcinogen to humans. FDA scientists reviewed the scientific information included in IARC's review in 2021 when it was first made available and identified significant shortcomings in the studies on which IARC relied.
Sources: en.wikipedia.org
The breakthrough for large molecule laser desorption ionization came in 1987 when Koichi Tanaka of Shimadzu Corp. and his co-workers used what they called the "ultra fine metal plus liquid matrix method" that combined 30 nm cobalt particles in glycerol with a 337 nm nitrogen laser for ionization. Using this laser and matrix combination, Tanaka was able to ionize biomolecules as large as the 34,472 Da protein carboxypeptidase-A. Tanaka received one-quarter of the 2002 Nobel Prize in Chemistry for demonstrating that, with the proper combination of laser wavelength and matrix, a protein can be ionized. Karas and Hillenkamp were subsequently able to ionize the 67 kDa protein albumin using a nicotinic acid matrix and a 266 nm laser. Further improvements were realized through the use of a 355 nm laser and the cinnamic acid derivatives ferulic acid, caffeic acid and sinapinic acid as the matrix. The availability of small and relatively inexpensive nitrogen lasers operating at 337 nm wavelength and the first commercial instruments introduced in the early 1990s brought MALDI to an increasing number of researchers. Today, mostly organic matrices are used for MALDI mass spectrometry.
== Side effects == Adverse events are generally caused by incorrect dosing. Long-term suppression of TSH values below normal values frequently causes cardiac side effects and contributes to decreases in bone mineral density (low TSH levels are also well known to contribute to osteoporosis). Too high a dose of levothyroxine causes hyperthyroidism. Overdose can result in heart palpitations, abdominal pain, nausea, anxiety, confusion, agitation, insomnia, weight loss, and increased appetite. Acute massive overdose may be life-threatening; treatment should be symptomatic and supportive. Massive overdose can be associated with increased sympathetic activity, thus may require treatment with beta blockers. The effects of overdosing appear 6 hours to 11 days after ingestion.
== History == Diclofenac was first synthesized by Alfred Sallmann and Rudolf Pfister in 1973. The name "diclofenac" derives from its chemical name: 2-(2,6-dichloranilino) phenylacetic acid. It was patented in Germany in 1978 by Ciba-Geigy (now Novartis). It came into medical use in the United States in 1988. GlaxoSmithKline purchased the rights in 2015. It is available as a generic medication.
=== Other acquisitions and mergers === In 2014, Einstein Noah Restaurant Group was acquired by JAB Holding Company and BDT Capital Partners. On August 5, 2021, Einstein Bros. announced that it had merged with Panera Bread and Caribou Coffee to form Panera Brands.
A letter from a Mrs. Grace Black found in the Bentley Historical Library's historical archives illustrates the struggles of finding housing with children amid the highway construction:Sept 1950Governor Williams:Please consider a family of 6 who are desperately in need of a house to rent. Husband, wife, and four lonely children, who have been turned down because we have children. We are now living in a house of the Edsel Ford Express Highway. We have our notice to move on out before the 23rd of Oct. So far we haven't found a place to move. Nobody want to rent us because we have children. My children aren't destructive but nobody will give us a chance to find out if they are or not. We are so comfortable here. It's the first freedom we've enjoyed since we've had children. My husband work at children's hospital only mak $60 a week. Sixty dollars we are paying $50 a month which we don't mind because we are comfortable. This will be demolished if we were able we would buy this house. But are not. So if anything you can do will be appreciated from the depths of our hearts. You have done so much to help the lower income families. We are deeply grateful wishing you God's speed. This is urgent! Please give this your immediate consideration.Thank youMrs. Grace Black (a worried mother) I-75, Ford Field, and Comerica Park now occupy most of the area where Paradise Valley once stood. Historian Thomas Sugrue notes that of the families displaced by the razing of the Paradise Valley neighborhood:
Sources: en.wikipedia.org
Lyophilized material is typically kept refrigerated and away from light in the sealed vial provided. Dissolved material is generally used within a limited period rather than stored long term.
Mass spectrometry gives the molecular weight, and mapping after digestion gives sequence coverage. Reversed-phase chromatography then supplies a purity profile.
Different groups report purity with different methods and thresholds, and full validation data are seldom published. Direct comparison of activity across batches therefore stays uncertain.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.